MIRTAZAPINE description, usages, side effects, indications, overdosage, supplying and lots more!

Menu
Search

MIRTAZAPINE

REMEDYREPACK INC.


FULL PRESCRIBING INFORMATION: CONTENTS*




FULL PRESCRIBING INFORMATION

BOXED WARNING




Antidepressants increased the risk compared to placebo of suicidal thinking and behavior (suicidality) in children, adolescents, and young adults in short-term studies of major depressive disorder (MDD) and other psychiatric disorders.  Anyone considering the use of mirtazapine orally disintegrating tablets or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. Short-term studies did not show an increase in the risk of suicidality with antidepressants compared to placebo in adults beyond age 24; there was a reduction in risk with antidepressants compared to placebo in adults aged 65 and older. Depression and certain other psychiatric disorders are themselves associated with increases in the risk of suicide. Patients of all ages who are started on antidepressant therapy should be monitored appropriately and observed closely for clinical worsening, suicidality, or unusual changes in behavior. Families and caregivers should be advised of the need for close observation and communication with the prescriber. Mirtazapine is not approved for use in pediatric patients. (See Warnings: Clinical Worsening and Suicide Risk, Precautions: Information for Patients, and Precautions: Pediatric Use)

MIRTAZAPINE DESCRIPTION



MIRTAZAPINE








CLINICAL PHARMACOLOGY





2

2 31A1B

1

1







In vitro






GERIATRIC USE




PRECAUTIONSDOSAGE AND ADMINISTRATION

CLINICAL PHARMACOLOGYDOSAGE AND ADMINISTRATION

CLINICAL STUDIES








INDICATIONS & USAGE





CLINICAL PHARMACOLOGY





CLINICAL PHARMACOLOGY

MIRTAZAPINE CONTRAINDICATIONS




WARNINGS






 




All patients being treated with antidepressants for any indication should be monitored appropriately and observed closely for clinical worsening, suicidality, and unusual changes in behavior, especially during the initial few months of a course of drug therapy, or at times of dose changes, either increases or decreases.






Families and caregivers of patients being treated with antidepressants for major depressive disorder or other indications, both psychiatric and nonpsychiatric, should be alerted about the need to monitor patients for the emergence of agitation, irritability, unusual changes in behavior, and the other symptoms described above, as well as the emergence of suicidality, and to report such symptoms immediately to health care providers. Such monitoring should include daily observation by families and caregivers.
 

PRECAUTIONS




Information for Patients

PRECAUTIONS: Pediatric Use

CLINICAL PHARMACOLOGYDOSAGE AND ADMINISTRATION






22CLINICAL PHARMACOLOGYDOSAGE AND ADMINISTRATION


INFORMATION FOR PATIENTS
















CLINICAL PHARMACOLOGYIn vitroin vitro




2



in vitro in vitro in vivo
2



PREGNANCY



Pregnancy Category C

22

NURSING MOTHERS





PEDIATRIC USE





PRECAUTIONS-Increased Appetite/Weight Gain

MIRTAZAPINE ADVERSE REACTIONS





















WARNINGSPRECAUTIONS
Body as a Whole:frequent:infrequent: rare:

Cardiovascular System:frequent: infrequent:rare:

Digestive System:frequent: infrequent: rare:

Endocrine System:rare:

Hemic and Lymphatic System: rare:

Metabolic and Nutritional Disorders:frequent: infrequent: rare:

Musculoskeletal System:frequent: infrequent:rare:

Nervous System:frequent: infrequent: rare:

Respiratory System:frequent: infrequent: rare:

Skin and Appendages:frequent: infrequent: rare:

Special Senses:infrequent: rare:

Urogenital System:frequent:infrequent: rare:





DRUG ABUSE AND DEPENDENCE








OVERDOSAGE











Physicians’ Desk Reference (



DOSAGE & ADMINISTRATION






PRECAUTIONSCLINICAL PHARMACOLOGY
CLINICAL PHARMACOLOGY

HOW SUPPLIED






30 mg Tablets –






Storage
 



PACKAGE LABEL.PRINCIPAL DISPLAY PANEL SECTION
















MIRTAZAPINE

MIRTAZAPINE

MIRTAZAPINE

MIRTAZAPINE TABLET

Product Information

Product Type Human prescription drug label Item Code (Source) NDC:49349-062(NDC:60505-0248)
Route of Administration ORAL DEA Schedule

Active Ingredient/Active Moiety

Ingredient Name Basis of Strength Strength
MIRTAZAPINE Mirtazapine 30 mg

Inactive Ingredients

Ingredient Name Strength
ANHYDROUS LACTOSE
HYDRATED SILICA
CROSCARMELLOSE SODIUM
FD&C BLUE NO. 2
FD&C YELLOW NO. 6
HYPROMELLOSE 2208 (100 MPA.S)
MAGNESIUM STEARATE
cellulose, microcrystalline
POLYDEXTROSE
polyethylene glycol
STARCH, CORN
SODIUM LAURYL SULFATE
titanium dioxide
triacetin

Product Characteristics

Color Size Imprint Code Shape
brown 11 mm MI;30;APO OVAL

Packaging

# Item Code Package Description Marketing Start Date Marketing End Date
1 NDC:49349-062-02 30 in 1 BLISTER PACK

Marketing Information

Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
ANDA ANDA077666 2010-11-10


PLEASE, BE CAREFUL!
Be sure to consult your doctor before taking any medication!
Copyright © 2014. drugs-library.com. All rights reserved. Information on drugs-library.com is provided for educational purposes only and is not to be used for medical advice, diagnosis or treatment.
Support info@drugs-library.com.